Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 1, 2006 Jack Uldrich	Altair Gets a Boost The partnership with Phoenix Motors is off to a good start but investors are cautioned to make sure a couple of milestones are met before investing.
BusinessWeek March 12, 2007 Gene G. Marcial	Charging The Batteries At Altair Altair nanotechnologies, a tiny outfit in the emerging nano market, has caught the eye of the likes of Alcoa and Eli Lilly.
The Motley Fool April 5, 2005 Wherrett & Yelovich	My Stock Rose 278% Yesterday! China-based Advanced Battery announced signing a development agreement to use Altair Nanotechnologies' battery electrode nano-materials for its existing polymer lithium-Ion battery product lines. Shares closed at $2.08 up from $0.55.
The Motley Fool May 31, 2005 Seth Jayson	History Repeats at Altair There will be plenty of time to invest in Altair Nanotechnologies if or when it actually writes some sustainable, revenue-producing deals. Until then, watch your wallet.
The Motley Fool December 21, 2005 Jack Uldrich	Yet Another Altair Press Release The nanotech firm's love affair with fluff-filled media statements continues. Altair's stock has now plummeted nearly 70% from previous highs.
The Motley Fool March 5, 2007 Jack Uldrich	A Model for Altair Another lithium-ion battery technology developer is hitting on all cylinders -- just another reason for investors to be cautious about investing in Altair.
The Motley Fool May 12, 2005 Seth Jayson	Altair Still All Air No guidance was announced by the nanotech materials producer, just the usual talk about "expecting" some "deals" and then plenty of exciting-sounding descriptions of technology that may or may not ever pay off for investors.
The Motley Fool March 17, 2005 Wherrett & Yelovich	The Sound of Music for Altair Just another reorganization for the nano company or real changes ahead? Investors, take note.
The Motley Fool August 15, 2005 Seth Jayson	Altair Stays the Course No great new things at nanotech company Altair, but the quarter's not a complete disaster, either. Investors just need to realize that this is an unproven speculation with a history of hype. Bid on the shares accordingly, if at all.
The Motley Fool March 14, 2007 Seth Jayson	Quick Take: More Fuzzy Math at Altair The recently released 10-K highlights bits of fuzzy math over the much-hyped sale of NanoSafe battery packs to Phoenix Motors. Investors, take note.
The Motley Fool March 9, 2007 Seth Jayson	Quick Take: Altair Needs an Altoid This company's financial results still stink. But that doesn't stop the hype machine. If expensive, money-losing penny stocks are what's hot "Inside Wall Street," make sure you stand outside.
IEEE Spectrum November 2007 Peter Fairley	Electric-Car Maker Touts 10-Minute Fill-up Thanks to an uncommonly stable lithium chemistry and high-surface-area nanopatterned electrodes, Altair Nanotechnologies' lithium-ion batteries for electric vehicles charge up fast. Very fast. Skeptics say substation-scale power levels needed are unrealistic.
The Motley Fool June 14, 2004 Brian Gorman	Elan Teams Up With Lilly The companies' manufacturing agreement may be more of a positive sign for Eli Lilly than it is for Elan.
IEEE Spectrum November 2007 Peter Fairley	California to Rule On Fate of EVs Hybrids are going mainstream, major automakers are once again engineering battery EVs, and start-ups such as Tesla Motors and Phoenix are bringing them to market. Can California's ambitious and controversial zero-emissions vehicle mandate help?
IndustryWeek January 1, 2006 John Teresko	Hybrids, Electrics: Nano Power? Nanotechnology boosts the operating characteristics of lithium-ion batteries.
The Motley Fool April 27, 2007 Jack Uldrich	Altair's Thin Coating The nanotech firm and Sherwin-Williams promise better paints. But some investors are suspicious.
The Motley Fool March 23, 2011 Brian Orelli	Eli Lilly: Great Plan, Poor Execution Eli Lilly shuns large mergers, but hasn't produced drugs on its own.
Military & Aerospace Electronics June 2009	U.S. Army employs Altair Nano military batteries in M119 howitzer U.S. military officials found the military battery they needed for the U.S. Army's M119 105 millimeter lightweight gun digitization program at Altair Nanotechnologies Inc. in Reno, Nev.
The Motley Fool January 28, 2010 Brian Orelli	The Biggest Development-Stage Drugmaker, Ever Eli Lilly seems to have a lot more in common with its development-stage little brothers than it does with its big pharma brethren.
Military & Aerospace Electronics September 2009	Navy Shipboard Power Designers Look to Altair Nano for Warship UPS Power electronics designers at Altair Nanotechnologies will research and design a large-scale nano lithium titanate battery system for possible use as an uninterruptible power supply (UPS) for Navy warship applications.
The Motley Fool October 21, 2010 Brian Orelli	Nice Earnings, Eli Lilly, but ... Eli Lilly trounced analysts' earnings estimates today, but investors sighed -- and for good reason.
IEEE Spectrum January 2007 John Voelcker	Lithium Batteries for Hybrid Cars Hybrid cars need to travel farther in electric-only mode, and that means lithium-ion battery technologies have a lot riding on them.
The Motley Fool November 24, 2010 Brian Orelli	A Manly FDA Approval Eli Lilly has something to be thankful for this week; the Food and Drug Administration approved Axiron, its testosterone replacement therapy.
The Motley Fool March 24, 2005 Brian Gorman	Eli Lilly Turns to Japan The company's move to focus more resources on Japan makes good sense.
The Motley Fool August 13, 2010 Brian Orelli	Already a Slippery Slope for Eli Lilly The company gets a whiff of what its patent cliff might be like.
The Motley Fool May 24, 2011 Brian Orelli	If at First You Don't Succeed, Spin It Off Eli Lilly ditches Xigris by spinning off BioCritica.
The Motley Fool December 10, 2004 Brian Gorman	Cardinal Picks a Lilly Cardinal Health's deal with Lilly suggests the new fee-for-service model is gaining traction.
The Motley Fool April 14, 2005 Carl Wherrett	Toshiba's Battery Breakthrough Nanotechnology is making good on its promise -- at least in battery technology. Watch out for the other battery manufacturers to come up with their own breakthroughs.
The Motley Fool March 14, 2011 Brian Orelli	This Deal Is No Dog Eli Lilly picks up Johnson & Johnson's European animal-health business.
The Motley Fool November 5, 2010 Brian Orelli	Better Late Than Never for Cymbalta Eli Lilly gets an expanded approval for Cymbalta.
The Motley Fool March 18, 2011 Brian Orelli	Forget Getting Approved, for Now The FDA wants more information on Eli Lilly's Amyvid.
The Motley Fool July 23, 2010 Brian Orelli	Eli Lilly Looks Great Today, but I'm Concerned About Tomorrow Eli Lilly is firing on all cylinders, but is there a blowout in its future?
The Motley Fool November 30, 2009 Brian Orelli	Anxious No Longer Eli Lilly adds another approval onto Cymbalta.
The Motley Fool January 13, 2011 Brian Orelli	FDA Panel Gives Eli Lilly Indigestion Eli Lilly's new acquisition causes a tummy ache.
The Motley Fool November 3, 2010 April Taylor	Altair Nanotechnologies Shares Popped: What You Need to Know On Monday, Altair announced that it would do a 4-for-1 reverse split of its shares to increase its stock price and ensure that it keeps its Nasdaq listing.
The Motley Fool October 28, 2005 Jack Uldrich	A New Nanotech Fund The PowerShares fund tries to make it easier to invest in nanotech. But the choice of companies could have been better.
The Motley Fool April 10, 2007 Jack Uldrich	PG&E Plugs a Problem Pacific Gas & Electric shows how a new hybrid car could also power homes and businesses. Investors, this is a trend to watch.
The Motley Fool April 15, 2005 Brian Gorman	Relief Pitch for Eli Lilly A ruling upholding the Zyprexa patent is good news for Lilly, but promising drugs in the pipeline are even more encouraging. Investors, take note.
The Motley Fool December 12, 2008 Brian Orelli	A Long-Term Play for Your Port Long-term prospects look better than the near term ones for Eli Lilly and its investors.
The Motley Fool May 18, 2005 Brian Gorman	Lilly Launches Automation Eli Lilly's drive to improve efficiency makes the company worth watching.
The Motley Fool January 28, 2011 Brian Orelli	Avoid This Falling Knife for Now 2011 could be just the start of a long slide for Lilly. And 2012 will see difficult year-over-year comparison.
The Motley Fool January 10, 2008 Brian Orelli	Good News for Lucky Men Eli Lilly's erectile dysfunction drug can now be taken daily.
The Motley Fool October 24, 2008 Brian Orelli	Lilly's Results Run the Gamut The company's GAAP EPS and adjusted EPS are at polar extremes.
The Motley Fool January 13, 2012 Morgan Housel	5 Companies You Can Buy Today Cheap by the numbers.
The Motley Fool June 10, 2005 Stephen D. Simpson	The High Cost of Diabetes Settling claims related to Zyprexa was probably the best of a bad set of choices for Eli Lilly. Investors need to remember to incorporate this as a risk factor for all drug companies.
The Motley Fool November 9, 2010 Brian Orelli	Forget R&D; Buy Your Way Into Diagnostics Eli Lilly is expanding its diagnostics business by picking up privately held Avid Radiopharmaceuticals.
The Motley Fool May 20, 2009 Brian Orelli	Joining to Treat, and Beat, Diabetes Medical-device maker Medtronic and drugmaker Eli Lilly are teaming up to co-promote the companies' diabetes products to doctors and patients.
The Motley Fool August 23, 2010 Jordan DiPietro	How Safe Are Eli Lilly's Dividends? Check out how Eli Lilly stacks up
The Motley Fool May 16, 2011 Brian Orelli	Diabetes Drug Duo Duels It Out in Court Amylin sticks up to partner Eli Lilly.
The Motley Fool July 26, 2007 Brian Lawler	Lilly Doesn't Wilt The second quarter was another good one for Eli Lilly. Top-line and bottom-line both grew.